The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
“…these are … complementary regimens that could be given to suitable patients,” Dr. Dimopoulos said, explaining how DREAMM-7 fits patients progressing on lenalidomide without prior anti-CD38 exposure, while belantamab mafodotin combined with pomalidomide and dexamethasone suits those resistant to both lenalidomide and anti-CD38.
Dr. Saad Usmani, chief of the Myeloma Service at Memorial Sloan Kettering Cancer Center, discusses the FDA approval of iberdomide plus dexamethasone in relapsed multiple myeloma. The FDA approval was announced in August 2026 and based on findings from the SUCCESSOR-2 trial.
Beyond the scientific and educational programming, Dr. Garcia-Manero reflected on the opportunity to recognize leaders in the field. He described it as a “great honor” to introduce Alan List, MD, and Neil Young, MD, two prominent investigators whose contributions to the field were recognized during the meeting.
“We recommend artificial tears,” Dr. Dimopoulos said, adding that his team may also hold the drug when needed and provide patients with practical advice for managing ocular symptoms.
Building upon its previous approval in the relapsed or refractory setting, this expanded indication is based on data from the global phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials.
“… where is the threshold where you can get really good MRD negativity, good responses in this older patient population without causing ocular side effects?” Dr. Usmani said of efforts to optimize the dosing schedule in the DREAMM-9 study.
SOHO Insider is the official media platform of the Society of Hematologic Oncology. The SOHO Insider Editorial Board is comprised of leading hematologists. Learn more about our editorial board and SOHO Insider platforms.
To access the SOHO Career Center click the following link.
